<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03161379</url>
  </required_header>
  <id_info>
    <org_study_id>J1756</org_study_id>
    <secondary_id>IRB00130075</secondary_id>
    <nct_id>NCT03161379</nct_id>
  </id_info>
  <brief_title>GVAX Pancreas Vaccine (With CY) in Combination With Nivolumab and SBRT for Patients With Borderline Resectable Pancreatic Cancer</brief_title>
  <official_title>A Phase II Clinical Trial of GVAX Pancreas Vaccine (With Cyclophosphamide) in Combination With Nivolumab and Stereotactic Body Radiation Therapy (SBRT) Followed by Definitive Resection for Patients With Borderline Resectable Pancreatic Adenocarcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety and clinical activity of FOLFIRINOX along&#xD;
      with a whole cell vaccine with immune modulating doses of cyclophosphamide and nivolumab&#xD;
      combined with Stereotactic Body Radiation Therapy (SBRT) in patients with pancreatic cancer.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">February 2, 2018</start_date>
  <completion_date type="Anticipated">January 2023</completion_date>
  <primary_completion_date type="Anticipated">January 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
    <masking_description>Open Label</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>CD8 count (cells/mm^3) in the tumor microenvironment</measure>
    <time_frame>4 years</time_frame>
    <description>Whether the CD8 count in the tumor microenvironment is higher for patients with BR-PDAC treated with neoadjuvant chemotherapy, SBRT, and Cy/GVAX/nivolumab immunotherapy as compared to archived samples from patients treated with FOLFIRINOX and SBRT.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pathologic complete response (pCR) rate at surgical resection</measure>
    <time_frame>4 years</time_frame>
    <description>Pathologic complete response (pCR) rate at surgical resection of BR-PDAC treated with neoadjuvant sequential chemotherapy, SBRT, and Cy/GVAX/nivolumab immunotherapy.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Pancreatic Cancer</condition>
  <arm_group>
    <arm_group_label>CY, Nivolumab, GVAX, and SBRT</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CY, Nivolumab, GVAX, and SBRT</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide</intervention_name>
    <description>Cyclophosphamide 200 mg/m2 will be administered one day prior to vaccination (day 0). First dose will be given within 4 to 6 weeks after chemotherapy. 3 weeks after the first dose of immunotherapy the second dose will be given.</description>
    <arm_group_label>CY, Nivolumab, GVAX, and SBRT</arm_group_label>
    <other_name>CY</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nivolumab</intervention_name>
    <description>Nivolumab (240 mg) will be administered one day prior to vaccination. First dose will be given within 4 to 6 weeks after chemotherapy. 3 weeks after the first dose of immunotherapy the second dose will be given.</description>
    <arm_group_label>CY, Nivolumab, GVAX, and SBRT</arm_group_label>
    <other_name>OPDIVO</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GVAX Pancreas Vaccine</intervention_name>
    <description>Vaccine will be administered one day after cyclophosphamide and nivolumab. 3 weeks after the first dose of immunotherapy the second dose will be given.</description>
    <arm_group_label>CY, Nivolumab, GVAX, and SBRT</arm_group_label>
    <other_name>PANC 10.05 pcDNA-1/GM-Neo and PANC 6.03 pcDNA-1/GM-Neo vaccine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Stereotactic Body Radiation (SBRT)</intervention_name>
    <description>SBRT (6.6 Gy over 5 days) will be started during the second dose of immunotherapy (3 weeks after the first dose of immunotherapy).</description>
    <arm_group_label>CY, Nivolumab, GVAX, and SBRT</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Have histologically proven pancreatic cancer that is borderline resectable&#xD;
&#xD;
          -  No more than 1 month/cycle (28 days) of systemic therapy for pancreatic cancer&#xD;
&#xD;
          -  Age &gt;18 years old.&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) performance status 0-1.&#xD;
&#xD;
          -  Patients must have adequate organ and marrow function defined by study-specified&#xD;
             laboratory tests.&#xD;
&#xD;
          -  Woman of child bearing potential must have a negative pregnancy test.&#xD;
&#xD;
          -  Must use an acceptable form of birth control while on study.&#xD;
&#xD;
          -  Must be candidate for Stereotactic Body Radiation Therapy (SBRT)&#xD;
&#xD;
          -  Ability to understand and the willingness to sign a written informed consent document.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Had major surgery within the last 28 days&#xD;
&#xD;
          -  Had an investigational drug or device within the past 28 days&#xD;
&#xD;
          -  Prior treatment with immunotherapy agents (including, anti-PD-1, anti-PD-L1,&#xD;
             anti-PD-L2, anti-CTLA4, etc)&#xD;
&#xD;
          -  Completed more than 1 month/cycle (28 days) of chemotherapy for pancreas cancer&#xD;
&#xD;
          -  Patient on an immunosuppressive systemic treatment, such as steroids, in the past 2&#xD;
             years.&#xD;
&#xD;
          -  Other cancer diagnosis requiring treatment within two years&#xD;
&#xD;
          -  History of allergic reactions related to the drugs (Nivolumab, Cyclophosphamide,&#xD;
             GM-hetastarch, corn, dimethyl sulfoxide, fetal bovine serum, trypsin (porcine origin),&#xD;
             yeast or any other component of the GVAX vaccine) in this study.&#xD;
&#xD;
          -  Patients receiving growth factors within the last 14 days.&#xD;
&#xD;
          -  Currently have or have history of certain study-specified heart, liver, kidney, lung,&#xD;
             neurological, psychological, immune or other medical conditions.&#xD;
&#xD;
          -  Pregnant or breastfeeding.&#xD;
&#xD;
          -  Have known history of infection with HIV, hepatitis B, or hepatitis C.&#xD;
&#xD;
          -  Unwilling or unable to follow the study schedule for any reason.&#xD;
&#xD;
          -  Presence of tissue or organ allograft, regardless of need for immunosuppression&#xD;
             (including corneal allograft)&#xD;
&#xD;
          -  Squamous pancreatic cancer or adenosquamous pancreatic cancer with malignant squamous&#xD;
             cells &gt;30%&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Daniel Laheru, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Arsen Osipov, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21231</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical College of Wisconsin</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53226</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>May 18, 2017</study_first_submitted>
  <study_first_submitted_qc>May 18, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">May 19, 2017</study_first_posted>
  <last_update_submitted>September 2, 2021</last_update_submitted>
  <last_update_submitted_qc>September 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Neoadjuvant therapy</keyword>
  <keyword>immunotherapy</keyword>
  <keyword>Cytoxan</keyword>
  <keyword>Cyclophosphamide</keyword>
  <keyword>Pancreatic Vaccine</keyword>
  <keyword>SBRT</keyword>
  <keyword>GVAX</keyword>
  <keyword>Nivolumab</keyword>
  <keyword>borderline resectable</keyword>
  <keyword>Radioimmunotherapy</keyword>
  <keyword>Vaccine</keyword>
  <keyword>Antibody</keyword>
  <keyword>Anti-PD-1</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pancreatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Nivolumab</mesh_term>
    <mesh_term>Pancrelipase</mesh_term>
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

